SCHEMBL3432078

SCHEMBL3432078

CNC(=O)c1cccc(-n2nnc3c(N4CCOCC4)nc(-c4cccc(O)c4)nc32)c1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.52
PIK3CA P42336 19/20 0.49
MTOR P42345 12/20 0.49
PIK3CG P48736 7/20 0.49
PIK3CD O00329 2/20 0.49
PIK3R1 P27986 1/20 0.45
PIK3C2B O00750 1/20 0.44
CCNE2 O96020 1/20 0.44
PRKACA P17612 1/20 0.44
PRKACG P22612 1/20 0.44
PRKACB P22694 1/20 0.44
CCNE1 P24864 1/20 0.44
CDK2 P24941 1/20 0.44
KDR P35968 1/20 0.44
PIK3CB P42338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3408990 0.90 PIK3CA (0.50) HDAC1PIK3CAMTORPIK3CGPIK3CD
SCHEMBL3407818 0.90 PIK3CA (0.52) HDAC1PIK3CAMTORPIK3CGPIK3CD
SCHEMBL3431202 0.90 PIK3CA (0.52) HDAC1PIK3CAMTORPIK3CGPIK3CD
SCHEMBL3424016 0.88 PIK3CA (0.55) HDAC1PIK3CAMTORPIK3CGPIK3CD
SCHEMBL8184114 0.86 PIK3CA (0.54) HDAC1PIK3CAMTORPIK3CGPIK3CD
SCHEMBL3402190 0.82 PIK3CA (0.52) HDAC1PIK3CAMTORPIK3CGPIK3CD
SCHEMBL3408347 0.81 PIK3CA (0.57) HDAC1PIK3CAMTORPIK3CGPIK3CD
SCHEMBL3427732 0.79 PIK3CA (0.48) HDAC1PIK3CAMTORPIK3CG
SCHEMBL3431299 0.79 KMO (0.47) HDAC1PIK3CAMTORPIK3CGPIK3CD
SCHEMBL3425301 0.78 PIK3CA (0.54) HDAC1PIK3CAMTORPIK3CGPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2252296-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES Wyeth LLC (US) 2010-11-24 EP claimed
WO-2009091788-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-23 WO claimed
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-16 US claimed
EP-2252296-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES Wyeth LLC (US) 2010-11-24 EP disclosed
WO-2009091788-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-23 WO disclosed
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES MTOR, PIK3CA, PIK3CD HDAC1 874/4885PIK3CA 2/4885MTOR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.